GLP-1 Cardiovascular Outcomes — Guidelines vs. Evidence
How diabetes and obesity guidelines incorporate GLP-1 receptor agonist cardiovascular outcome trials.
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
RAGMD evidence position
GLP-1 receptor agonists reduce major adverse cardiovascular events in high-risk populations with established CVD or diabetes.
Guideline vs. evidence
| Guideline | Society position | RAGMD evidence |
|---|---|---|
| ADA Standards of Care | Recommends GLP-1 RAs with proven CV benefit for patients with T2D and established ASCVD or high risk. | LEADER (liraglutide) and SUSTAIN-6 (semaglutide) established CV benefit in diabetes populations; SELECT extended to obesity without diabetes.Open evidence analysis → |
| AACE | Supports GLP-1 RAs for glycemic control with weight and CV benefits in appropriate patients. | RAGMD indexes agent-specific CVOTs — benefit magnitude and population differ between liraglutide, semaglutide, and dulaglutide.Open evidence analysis → |
| ACC/AHA | Incorporates GLP-1 RAs in obesity management algorithms when weight loss and CV risk reduction are goals. | SELECT trial (semaglutide 2.4mg) demonstrated 20% MACE reduction in overweight/obese adults without diabetes.Open evidence analysis → |
Key studies
- LEADER liraglutide CVOT · PMID 27295427
- SELECT semaglutide obesity CVOT · PMID 37952131